News Release
March 16, 2007
Nippon Shinyaku and Teva terminate HMN-214 License Agreement
Nippon Shinyaku Co., Ltd. (Head Office: Kyoto, Japan; President Mr. Kazuto Hatsuyama) announced on March 16, 2007 that Nippon Shinyaku and Teva Pharmaceutical Industries Ltd. (Headquarters; Jerusalem, Israel, President & CEO Mr. Shlomo Yanai) terminated the License Agreement on Nippon Shinyaku’s anti-cancer agent, HMN-214, which was concluded between Nippon Shinyaku and IVAX Corporation (Florida, USA) in September 2004. IVAX was acquired by Teva in January 2006. Nippon Shinyaku and Teva mutually decided to terminate the License Agreement.
HMN-214 is a novel anti-cancer agent discovered by Nippon Shinyaku and licensed to IVAX after the Phase 1 study in the U.S.